The Antibiotic Drought Of 2008: Plenty Of Action But No NME Approvals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The atypically small number of new molecular entity approvals from FDA's Office of Antimicrobial Products in 2008 belies the reviewers' full slate of NDAs, particularly of novel antibiotics